<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454463</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD Database 3</org_study_id>
    <secondary_id>U01DK061732</secondary_id>
    <secondary_id>U01DK061713</secondary_id>
    <secondary_id>U01DK061737</secondary_id>
    <secondary_id>U01DK061718</secondary_id>
    <secondary_id>U01DK061734</secondary_id>
    <secondary_id>U01DK061738</secondary_id>
    <secondary_id>U01DK061728</secondary_id>
    <secondary_id>U01DK061731</secondary_id>
    <secondary_id>U24DK061730</secondary_id>
    <nct_id>NCT04454463</nct_id>
  </id_info>
  <brief_title>Nonalcoholic Fatty Liver Disease (NAFLD) Database 3</brief_title>
  <official_title>Nonalcoholic Fatty Liver Disease (NAFLD) Database 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients
      suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the
      cooperative effort of a multidisciplinary and multicenter group of collaborators, the
      etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular
      its more severe form of NASH and its complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To enroll at least 2250 patients (1500 adult patients and 750 pediatric patients) with a
           diagnosis of NAFLD, supported by a standard of care liver biopsy, with a broad range of
           severity. Core data collection will include clinical, demographic, laboratory, imaging,
           and histological features

        -  To increase the population diversity of the NAFLD Database 2 to provide greater
           representation of Hispanic, Native American, African American, and Asian patients
           recruited into the NAFLD Database 3

        -  To expand the current specimen bank comprised of liver tissue, serum, plasma, and DNA
           obtained from patients undergoing a liver biopsy with the specific goal of optimizing
           the collection of plasma or serum suitable for biomarker development studies by
           obtaining specimens in close temporal proximity to the performance of liver biopsy
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in alanine aminotransferase (ALT) levels from baseline to one year.</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>ALT measure in IU/L (higher ALT indicates worse outcomes)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2250</enrollment>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Adult patients with NAFLD</arm_group_label>
    <description>1500 patients 18 years and older at the time of enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric patients with NAFLD</arm_group_label>
    <description>750 patients 2 years or older and up to 17 years old at the time of enrollment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, liver tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be at least 2250 patients age 2 years or older with
        histologically confirmed NAFLD or NASH located in the United States:

          -  1500 patients 18 years and older at the time of enrollment.

          -  750 patients 2 years or older and up to 17 years old at the time of enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 years of age or older as of the initial screening interview and provision of consent

          -  Willingness to participate in the study for 1 or more years

          -  Histologic evidence of NAFLD or NASH based upon a standard of care liver biopsy

          -  Collection of serum and plasma up to 90 days before or 4- 90 days after standard of
             care liver biopsy

          -  Absence of regular or excessive use of alcohol within 2 years prior to initial
             screening

        Exclusion Criteria:

          -  Clinical or histological evidence of alcoholic liver disease: Regular and excessive
             use of alcohol within the 2 years prior to interview defined as alcohol intake greater
             than 14 drinks per week in a man or greater than 7 drinks per week in a woman.
             Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 1 ounce of
             distilled spirits, one 12-oz beer, or one 4-oz glass of wine

          -  Total parenteral nutrition for more than 1 month within a 6-month period before
             baseline liver biopsy

          -  Short bowel syndrome

          -  History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric
             surgery performed following enrollment is not exclusionary. Liver biopsies obtained
             during bariatric surgery cannot be used for enrollment because of the associated
             surgical or anesthetic acute changes and the weight loss efforts that precede
             bariatric surgery

          -  History of biliopancreatic diversion

          -  Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score equal to or
             greater than 10

          -  Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (patients
             with isolated antibody to hepatitis B core antigen, anti-HBc total, are not excluded)

          -  Evidence of chronic hepatitis C as marked by the presence of anti-HCV or HCV RNA in
             serum

          -  Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of
             the investigator)

          -  Wilson's disease

          -  Known glycogen storage disease

          -  Known dysbetalipoproteinemia

          -  Known phenotypic hemochromatosis (HII greater than 1.9 or removal of more than 4 g of
             iron by phlebotomy)

          -  Prominent bile duct injury (florid duct lesions or periductal sclerosis) or bile duct
             paucity

          -  Chronic cholestasis

          -  Vascular lesions (vasculitis, cardiac sclerosis, acute or chronic Budd-Chiari,
             hepatoportal sclerosis, peliosis)

          -  Iron overload greater than 3+

          -  Zones of confluent necrosis, infarction, massive or sub-massive, pan-acinar necrosis

          -  Multiple epithelioid granulomas

          -  Congenital hepatic fibrosis

          -  Polycystic liver disease

          -  Other metabolic or congenital liver disease

          -  Evidence of systemic infectious disease

          -  Known HIV positive

          -  Disseminated or advanced malignancy

          -  Concomitant severe underlying systemic illness that in the opinion of the investigator
             would interfere with completion of follow-up

          -  Active drug use or dependence that, in the opinion of the study investigator, would
             interfere with adherence to study requirements

          -  Any other condition, which in the opinion of the investigator would impede compliance
             or hinder completion of study

          -  Inability to complete the appropriate informed consent process
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Sanyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brent Tetri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Louis University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Adamo, NP, MS</last_name>
    <phone>410-502-9137</phone>
    <email>madamo1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Sharkey, BS</last_name>
    <phone>410-955-8183</phone>
    <email>esharke5@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego- Adults</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Carolyn Hernandez</last_name>
      <phone>619-471-0774</phone>
      <email>c1hernandez@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Rohit Loomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christy Rico</last_name>
      <phone>323-442-1100</phone>
      <email>Christy.Rico@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Norah Terrault, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Pediatrics</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Janis Durelle</last_name>
      <phone>619-543-5226</phone>
      <email>jdurelle@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Schwimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle Brandman, MD</last_name>
      <phone>415-514-1094</phone>
      <email>danielle.brandman@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Norah Terrault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University-Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (NWU)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mary Riordan</last_name>
      <phone>312-227-4558</phone>
      <email>mriordan@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mark Fishbein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University- Adults</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Regina Weber</last_name>
      <phone>317-278-3584</phone>
      <email>ginaw@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Naga Chalasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Carr, RN</last_name>
      <phone>317-944-4490</phone>
      <email>walkerlk@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Molleston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Theresa Cattoor</last_name>
      <phone>314-977-5239</phone>
      <email>theresa.cattooor@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ajay Jain, MJD</last_name>
      <phone>(314) 577-5647</phone>
      <email>ajay.jain@health.slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brent Tetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajay Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>April Carr</last_name>
      <phone>513-636-3195</phone>
      <email>april.carr@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Stavra Xanthakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marialena Mouzaki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alina Tuladhar</last_name>
      <phone>216-445-0688</phone>
      <email>tuladha@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Annette Bellar</last_name>
      <phone>(216) 636-5247</phone>
      <email>bellara@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Dasarathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erin Gettman</last_name>
      <phone>206-215-2980</phone>
      <email>erin@liverinstitutenw.org</email>
    </contact>
    <investigator>
      <last_name>Kris Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital- SEA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melissa Young</last_name>
      <phone>206-987-1037</phone>
      <email>melissa.young@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Niviann Blondet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://jhuccs1.us/nash/</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://www2.niddk.nih.gov/</url>
    <description>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NASH CRN is fully committed to resource sharing beyond the NASH CRN investigators. The NASH CRN will make deposits to the NIDDK Central Data Repository according to the requirements outlined in the NIDDK Data Sharing Policy published in July 2013.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within two years of end of the funding cycle.</ipd_time_frame>
    <ipd_access_criteria>All qualified investigators will be allowed access to the stored materials at the end of a pre-determined proprietary period.</ipd_access_criteria>
    <ipd_url>https://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

